ライフサイエンスコーパス: oral treatment

1 eek group (difference 3.7% [-4.8 to 12.2] vs oral treatment).

2 days, with an average of 4.0 +/- 3.0 days of oral treatment.

3 intravenous treatment and 2205 (6%) received oral treatment.

4 avenous steroids, whereas 6220 (8%) received oral treatment.

5 is and adjuvant-induced arthritis, following oral treatment.

6 y (38 artesunate and 49 quinine) followed by oral treatments.

7 confidence interval], 1.63 [1.55-1.72]), on oral treatment (1.23 [1.15-1.31]), and on diet alone (1.

8 ntained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week

9 ptoms and diagnosis, 3) health behaviors, 4) oral treatments, 5) oral prevention, and 6) patient perc

10 cted a randomized trial of directly observed oral treatment administered monthly to reduce vaginal in

11 up (difference 2.8% [95% CI -5.8 to 11.5] vs oral treatment), and 109 (95%) of 115 patients in the 8-

12 r future trial design and studies of chronic oral treatment are discussed.

13 Recovery of hearing on oral treatment at 2 months by intention-to-treat analysi

14 Subjects were randomly assigned to receive oral treatment for 3 years with risedronate (2.5 or 5 mg

15 y and increased permeability were induced by oral treatment for 4 days with dextran sulphate sodium (

16 Both oral treatment for 4 weeks and a single intravenous metf

17 The hamsters were randomized to oral treatment for 4 weeks with vehicle (n=11), NCX 899

18 OC000459 shows promise as a novel oral treatment for asthma and related disorders.

19 potential for use as a once- or twice-daily oral treatment for cancer.

20 An effective, safe, and oral treatment for CL is required.

21 tential for a safe and effective nonabsorbed oral treatment for diabetes and support the concept of e

22 ients at baseline, week 1, and week 2 of all-oral treatment for hepatitis C virus (HCV) infection.

23 od has recently been introduced as the first oral treatment for multiple sclerosis.

24 An oral treatment for neovascular age-related macular degen

25 inhibitor of glucosyltransferase, as a novel oral treatment for non-neuronopathic Gaucher's disease.

26 FTY720 (fingolimod), recently approved as an oral treatment for relapsing forms of multiple sclerosis

27 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosi

28 failure (two in the 8-week group; one in the oral treatment group).

29 f the 4-week and 8-week groups and 56 to the oral treatment group).

30 t 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 108 (94%) of 115 patients in the 4

31 roups) and seven (13%) of 56 patients in the oral treatment group; none were drug related.

32 roin addicts who were receiving conventional oral treatment (>or=6 months), but continued to inject s

33 d over 5% body weight reduction after 14-day oral treatment in diet-induced obese (DIO) mice.

34 s not superior to a psychiatrist's choice of oral treatment in patients with schizophrenia and schizo

35 less nephrotoxic than tacrolimus upon 3-week oral treatment in rats.

36 P; a ligand to engage and activate dectin-1, oral treatment in vivo) significantly decreased tumor we

37 cular and topical therapies were superior to oral treatments in reducing pain.

38 The availability of these various oral treatments is hoped to improve regimens that, if us

39 groups (n=7 each) for 3 weeks received daily oral treatment of 1 of these regimens: (1) control, vehi

40 Remarkably, a brief 9 d oral treatment of APPswe/PS1Deltae9 mice with pioglitazo

41 Oral treatment of C. difficile-infected mice with the PP

42 We also show that oral treatment of caged bees with pilocarpine, a muscari

43 Most importantly, oral treatment of chrysin to transgenic mice that expres

44 afe and effective chemotherapeutic agent for oral treatment of drug-resistant human lymphomas.

45 more potent, less neurotoxic agents for the oral treatment of drug-resistant malaria, we utilized co

46 Oral treatment of infected BALB/c mice with imipramine i

47 l provide data that challenge the entrenched oral treatment of iron deficiency anemia.

48 Oral treatment of MIA offspring with the human commensal

49 Prolonged oral treatment of mice with antifungal drugs resulted in

50 rity, control of cardiac rhythm, and routine oral treatment of multiple sclerosis.

51 Oral treatment of neonatal lambs with JNJ-53718678, or w

52 e beta hemoglobinopathies and useful for the oral treatment of other anemias.

53 Oral treatment of rats with increased IOP with the CaN i

54 omising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly othe

55 Long-term oral treatment of SFD-SP rats with a selective p38 MAPK

56 and in vivo for their potential uses in the oral treatment of sickle cell disease symptoms.

57 uppress GVHD while sparing the GVL, based on oral treatment of transplant donors with recipient Ags,

58 Not all practice guidelines on oral treatment of type 2 diabetes were consistent with a

59 ombosis a less burdensome and less expensive oral treatment option instead of a more expensive subcut

60 ueous solubility, limit their suitability as oral treatment option.

61 ively affect patients' quality of life, with oral treatment preferable to most patients with cancer.

62 Second-line oral treatments recommended include an opioid-antagonist

63 ledge, this is the first demonstration of an oral treatment reducing both LID and OFF time in patient

64 This oral treatment regimen also induced indefinite prolongat

65 We sought to develop a new and effective oral treatment regimen specific to children of different

66 This oral treatment strategy preserved QOL in treated patient

67 New oral treatments that target myeloma cells or bone marrow

68 ble adjustment, including the propensity for oral treatment, the risk of treatment failure among pati

69 r, particularly for patients who have failed oral treatment trials.

70 strategies, and the median time to starting oral treatment was 3 days (interquartile range, 0 to 4)

71 Definitive oral treatment was given at 36 h.

72 se in the placebo group (51 percent) in whom oral treatment was judged to have failed.

73 fected sleep-wake architecture in rats after oral treatment, which we have previously shown to be ind

74 Oral treatment with 1 mg of insulin twice per week for 2

75 Oral treatment with 2% sodium chloride (NaCl) for 7 days

76 The effects of oral treatment with 2'-fucosyllactose and 6'-sialyllacto

77 Daily oral treatment with 2'-fucosyllactose or 6'-sialyllactos

78 Oral treatment with 40 mg pyridoxin hydrochloride for 28

79 ts were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus

80 The oral treatment with 7 (8 mg/kg/d) in a mouse model of IB

81 Oral treatment with a broad spectrum antibiotic modifies

82 r TLR2(-/-) mice demonstrate the ability for oral treatment with a TLR2 agonist to confer antiapoptot

83 is study was undertaken to determine whether oral treatment with a water-soluble N-hydroxy-2,2,6,6-te

84 Once-daily oral treatment with aliskiren lowers blood pressure effe

85 bladder muscle damage caused by BDL, whereas oral treatment with CDCA worsens the defective muscle co

86 Following oral treatment with CE, expression of the mast cell prot

87 le sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3.

88 In vivo oral treatment with compound 2 resulted in significant g

89 Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i

90 onths) complete remission of the lymphoma by oral treatment with doxycycline monohydrate, 200 mg per

91 Oral treatment with either amoxicillin, 500 mg three tim

92 Moreover, oral treatment with either resveratrol or aspirin, the p

93 It can be concluded that a single dose, oral treatment with eltoprazine has beneficial antidyski

94 Although oral treatment with enalapril did not reduce focal trace

95 Natural gut microbiota were modified by oral treatment with enrofloxacin prior to sensitization

96 Oral treatment with enrofloxacin suppresses CS and produ

97 t study we investigated the effectiveness of oral treatment with ethinyl estradiol (EE) on EAE and th

98 teral fluid percussion injury in adult rats, oral treatment with EVT901 reduced neuronal death in the

99 Oral treatment with increasing doses of rifampicin resul

100 Oral treatment with INH2BP (0.5 g/kg, daily), starting a

101 Here we report that oral treatment with insulin prevents virus-induced insul

102 ed in Zucker (fa/fa) rats following a 14-day oral treatment with INT131.

103 Oral treatment with L-arginine improves endothelial dysf

104 lock size four) in a 2:1 ratio to once-daily oral treatment with linagliptin 5 mg or matching placebo

105 Oral treatment with lithium preferentially inhibited the

106 Here we report that oral treatment with LTA-deficient NCK2025 normalizes inn

107 Oral treatment with minocycline, an inhibitor of microgl

108 s in BALB/c nude mice was inhibited by daily oral treatment with nilotinib.

109 a proprietary computer-generated sequence to oral treatment with opicapone (5 mg, 25 mg, or 50 mg onc

110 eactions and challenge outcome and prolonged oral treatment with penicillin in the diagnostic evaluat

111 ENDA program were supplemented with a 7-day oral treatment with penicillin.

112 Single oral treatment with placebo or eltoprazine, at 2.5, 5 an

113 anling Min mice were administered 6 weeks of oral treatment with R-FB using 2.5-25 mg/kg of R-FB once

114 ndomly assigned (1:1:1) to 24 weeks of daily oral treatment with starting doses of 10 mg amiloride, 2

115 We show that oral treatment with sterol-based LXR agonists in mice si

116 were randomly assigned to receive 10 days of oral treatment with telithromycin (at a dose of 800 mg d

117 Concurrent oral treatment with the antioxidant CPI-1189 prevented a

118 and gsk3(WT) mice, before and after 1 wk of oral treatment with the beta-blocker propranolol.

119 Oral treatment with the NOS substrate L-arginine at 5 g/

120 Oral treatment with the pyrazolopyridine KDU731 results

121 We show that oral treatment with the therapeutic agent diacetyl-bis(4

122 In conclusion, oral treatment with UDCA prevents gallbladder muscle dam

123 At 3 months after irradiation rats received oral treatment with vehicle, PTX, or PTX in combination

124 Daily oral treatments with OSU-A9 at 25 or 50 mg/kg for 56 day

125 Daily oral treatments with OSU-HDAC42 and SAHA, both at 25 mg/

126 acute (intravenous) and long-term (6 months, oral) treatment with carvedilol versus placebo in 151 co